Literature DB >> 2206130

Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin-1 from cultured endothelial cells by inhibiting a big endothelin-1 converting enzyme.

R Ikegawa1, Y Matsumura, Y Tsukahara, M Takaoka, S Morimoto.   

Abstract

Time-dependent secretion of immunoreactive-endothelin (IR-ET) from cultured porcine aortic endothelial cells was markedly suppressed by phosphoramidon is due to proteinase inhibitor. Analysis of the culture supernatant with or without phosphoramidon by reverse-phase high performance liquid chromatography confirmed that the suppression of IR-ET secretion by phosphoramidon is due to a decreae in secretion of endothelin-1-like materials. The secretion of the C-terminal fragment (CTF, 22-39)-like materials of big ET-1 was also decreased by phosphoramidon, whereas there was an increased secretion of big ET-1-like materials. These data strongly suggest that phosphoramidon suppresses the secretion of ET-1 from cultured endothelial cells by inhibiting the conversion of big ET-1 to ET-1. It is most likely that phosphoramidon-sensitive metalloproteinase is responsible for the processing of big ET-1 in vascular endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2206130     DOI: 10.1016/0006-291x(90)91198-2

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  Solution conformation of human big endothelin-1.

Authors:  M L Donlan; F K Brown; P W Jeffs
Journal:  J Biomol NMR       Date:  1992-09       Impact factor: 2.835

Review 2.  Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?

Authors:  L E Spieker; G Noll; F T Ruschitzka; T F Lüscher
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 3.  Endothelins. Vascular actions and clinical implications.

Authors:  T Sakurai; K Goto
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

4.  Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC.3.4.24.11.

Authors:  Z A Abassi; E Golomb; R Bridenbaugh; H R Keiser
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

5.  The endothelin-converting enzyme from human umbilical vein is a membrane-bound metalloprotease similar to that from bovine aortic endothelial cells.

Authors:  K Ahn; K Beningo; G Olds; D Hupe
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

6.  Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm.

Authors:  C Plumpton; W G Haynes; D J Webb; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

7.  [D-Val22]big ET-1[16-38] inhibits endothelin-converting enzyme activity: a promising concept in the prevention of cerebral vasospasm.

Authors:  Michael Zimmermann; Carla Sabine Jung; Hartmut Vatter; Andreas Raabe; Volker Seifert
Journal:  Neurosurg Rev       Date:  2002-11-19       Impact factor: 3.042

8.  Contractile activity of big endothelin-1 on the human isolated bronchus.

Authors:  C Advenier; V Lagente; Y Zhang; E Naline
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

9.  Regional differences in endothelin converting enzyme activity in rat brain: inhibition by phosphoramidon and EDTA.

Authors:  T D Warner; G P Budzik; T Matsumoto; J A Mitchell; U Förstermann; F Murad
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

10.  Contractile activity of endothelin precursors in the isolated gallbladder of the guinea-pig: presence of an endothelin-converting enzyme.

Authors:  B Battistini; M Woods; L J O'Donnell; T D Warner; R Corder; A Fournier; M J Farthing; J R Vane
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.